Ser325

Site Information
ASVLtHsssGNsLKR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4725030

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	leukemia ( 3 ) , chronic myelogenous leukemia ( 3 ) , lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 2 ) , K562 (erythroid) ( 2 , 3 ) , lung ( 1 )

References
1	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
2	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
3	Moritz A (2005) CST Curation Set: 705; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info